Saruparib Appears Safe, Active in Advanced Breast Cancer
Saruparib may be safe and effective for patients with homologous recombination repair-deficient, HER2-negative breast cancer.
Saruparib may be safe and effective for patients with homologous recombination repair-deficient, HER2-negative breast cancer.
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Get ready to dive into cutting-edge research, connect with professionals worldwide, and hear from the best in the field. WCLC 2024 promises to be a
Acalabrutinib combination therapy elicits statistically significant improvement in progression-free survival for treatment-naive mantle cell lymphoma.
Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma.
AbstractBackground. Randomized clinical trials of novel treatments for solid tumors normally measure disease progression using the Response Evaluation Crit
For most smokers, quitting on the first attempt is likely to be unsuccessful, but a new study from The University of Texas MD Anderson Cancer…
Fox Chase Cancer Center researchers showed that estrogen is metabolized in lungs, contributing to the development of lung cancer in never smokers.
Cancer Cytopathology is an international cytopathology journal publishing research related to topics concerning the etiology of cancer, its diagnosis and prevention.